Entrectinib a Plausible Inhibitor for Osteopontin (SPP1) in Cervical Cancer—Integrated Bioinformatic Approach

Poleboyina, Pavan Kumar; Pasha, Akbar; Doneti, Ravinder; Pasumarthi, Deepthi; Pawar, Sunil

doi:10.1007/s12010-023-04541-7

Cited by 2 publications

(1 citation statement)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, secreted phosphoprotein 1 ( SPP1 ), an integrin-binding glycophosphoprotein overexpressed in TC that promotes tumorigenesis through the inhibition of differentiation factors of thyroid cells, represents an opportunity for drug repositioning ( 60 , 61 ). Although there are no current FDA drugs approved for inhibiting SPP1 , a recent publication showed a promising inhibitory drug for cervical cancer: entrectinib ( 26 ). This represents a highlight, as entrectinib is an FDA-approved drug for NTRK fusions in solid tumors, including TC ( 62 ).…”

Section: Classical Point Mutations In Thyroid Cancer: Windows Of Oppo...mentioning

confidence: 99%

Drug repositioning in thyroid cancer: from point mutations to gene fusions

Sánchez-Marín,

Silva-Cázares,

González-Del Carmen

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

The diagnosis of thyroid cancer (TC) has increased dramatically in recent years. Papillary TC is the most frequent type and has shown a good prognosis. Conventional treatments for TC are surgery, hormonal therapy, radioactive iodine, chemotherapy, and targeted therapy. However, resistance to treatments is well documented in almost 20% of all cases. Genomic sequencing has provided valuable information to help identify variants that hinder the success of chemotherapy as well as to determine which of those represent potentially druggable targets. There is a plethora of targeted therapies for cancer, most of them directed toward point mutations; however, chromosomal rearrangements that generate fusion genes are becoming relevant in cancer but have been less explored in TC. Therefore, it is relevant to identify new potential inhibitors for genes that are recurrent in the formation of gene fusions. In this review, we focus on describing potentially druggable variants and propose both point variants and fusion genes as targets for drug repositioning in TC.

show abstract